3415-45-0 Usage
Uses
Used in Digestive Health:
Glycodehydrocholic acid is used as a digestive aid for enhancing the emulsification of dietary fats, making them more accessible for enzymatic digestion. This process is crucial for the efficient absorption of fatty acids, cholesterol, and fat-soluble vitamins in the small intestine.
Used in Pharmaceutical Industry:
Glycodehydrocholic acid is used as a therapeutic agent for the treatment of certain liver and digestive disorders. Its role in the digestion and absorption of fats and fat-soluble vitamins makes it a potential candidate for managing conditions related to fat malabsorption or liver function impairment.
Used in Nutritional Supplements:
In the nutritional supplement industry, glycodehydrocholic acid may be used as an additive to support healthy digestion and absorption of fats and fat-soluble vitamins, particularly for individuals with specific dietary needs or conditions affecting fat digestion.
Check Digit Verification of cas no
The CAS Registry Mumber 3415-45-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,4,1 and 5 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 3415-45:
(6*3)+(5*4)+(4*1)+(3*5)+(2*4)+(1*5)=70
70 % 10 = 0
So 3415-45-0 is a valid CAS Registry Number.
3415-45-0Relevant academic research and scientific papers
Synthesis, anticancer activities, antimicrobial activities and bioavailability of berberine-bile acid analogues
Li, Qingyong,He, Wuna,Zhang, Li,Zu, Yuangang,Zhu, Qiaochu,Deng, Xiaoqiu,Zhao, Tengfei,Gao, Wenqing,Zhang, Baoyou
scheme or table, p. 573 - 580 (2012/08/08)
Fifteen berberine-bile acid analogues were synthesized. Anticancer activities of these analogues compared with berberine (BBR) were evaluated in vitro; among the analogues, A4, B4, and B5 had higher cytotoxicity than that of BBR. Most of the analogues showed higher antimicrobial activity against Staphylococcus aureus ATCC 25923 and Staphylococcus albus ATCC 8799 than that of BBR, but Bacillus subtilis AS 1.398 and Escherichia coli ATCC 31343 were not sensitive to all of the analogues. A4 and B4 were stable in the serum stability assay. B4 showed promising oral bioavailability in mice.
